Bilateral Rhegmatogenous Retinal Detachments after Systemic Pazopanib Treatment

Sun Young Ryu; Soo Jung Hong; Eun Jee Chung

doi:10.3341/jkos.2019.60.5.491

Journal List > J Korean Ophthalmol Soc > v.60(5) > 1122602

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ryu, Hong, and Chung: Bilateral Rhegmatogenous Retinal Detachments after Systemic Pazopanib Treatment

Case Report

Journal of the Korean Ophthalmological Society 2019; 60(5): 491-495.

Published online: 15 May 2019

DOI: https://doi.org/10.3341/jkos.2019.60.5.491

Bilateral Rhegmatogenous Retinal Detachments after Systemic Pazopanib Treatment

Sun Young Ryu, MD^1,², Soo Jung Hong, MD³, Eun Jee Chung, MD, PhD²

¹Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.

²Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

³Divison of Oncology-Hematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

Address reprint requests to Eun Jee Chung, MD, PhD. Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, #100 Ilsan-ro, Ilsandong-gu, Goyang 10444, Korea. Tel: 82-31-900-0964, Fax: 82-31-900-0343, eunjee095@gmail.com

Received 30 August 2018 Revised 22 October 2018 Accepted 17 April 2019

The Korean Ophthalmological Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

A case of bilateral rhegmatogenous retinal detachment is reported after pazopanib treatment of a patient with breast angiosarcoma.

Case summary

A 53-year-old female presented with bleeding in a right breast mass prior to an emergency room visit. She was diagnosed with metastatic breast angiosarcoma after a breast mass biopsy. She was treated with paclitaxel and radiation therapy. Systemic pazopanib treatment was added to treat lung metastasis. After 3 weeks, she felt sudden floaters in her right eye. In her fundus examination, there was vitreous hemorrhage, but no retinal detachment was noted. Five weeks later, she visited the clinic for a bilateral temporal visual field defect. A fundus examination showed bilateral retinal detachments with superonasal retinal tears. Both the patient and her family did not want surgery for her systemic condition because of her terminal cancer.

Conclusions

Retinal detachment has been reported as a rare complication after systemic pazopanib treatment, but there has been no previous report in the Republic of Korea, therefore this is the first case of bilateral retinal detachments after systemic pazopanib treatment.

Keywords: Anti-VEGF treatment, Pazopanib, Retinal detachment, Retinal tear

Figures and Tables

Figure 1

Wide fundus photographs after taking Pazopanib for 3 weeks. (A) Vitreous hemorrhage was noted on right eye. (B) No definite lesions on left eye. (C, D) No retinal detachment was noted on right eye.

Figure 2

Five weeks follow-up wide fundus photographs showing bilateral rhegmatogenous retinal detachments at nasal with retinal tears. (A) Right eye, (B) left eye.

Notes

This work was presented as a e-poster at 2018, 120th Annual meeting of the Korean ophthalmological society.

^{Conflicts of Interest} The authors have no conflicts to disclose.

References

1. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011; 71:443–454.

2. Gaertner KM, Caldwell SH, Rahma OE. A case of retinal tear associated with use of sorafenib. Front Oncol. 2014; 4:196.

3. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond). 2011; 25:1517–1518.

4. Fraunfelder FT, Fraunfelder FW. Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther. 2018; 34:432–435.

5. Hasan R. A retinal tear induced by pazopanib therapy: a case report. Med Forum. 2015; 16:13.

6. Mitry D, Charteris DG, Fleck BW, et al. The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Br J Ophthalmol. 2010; 94:678–684.

7. Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012; 307:1414–1419.

8. Ponsioen TL, Hooymans JM, Los LI. Remodelling of the human vitreous and vitreoretinal interface a dynamic process. Prog Retin Eye Res. 2010; 29:580–595.

9. VanderBeek BL. Oral fluoroquinolones, retinal detachments, and claims database studies. JAMA Ophthalmol. 2016; 134:422–423.

10. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol. 2012; 6:1325–1333.

11. Georgalas I, Paraskevopoulos T, Koutsandrea C, et al. Ophthalmic metastasis of breast cancer and ocular side effects from breast cancer treatment and management: mini review. Biomed Res Int. 2015; 2015:574086.

12. Novak MA, Welch RB. Complications of acute symptomatic posterior vitreous detachment. Am J Ophthalmol. 1984; 97:308–314.

13. Krohn J, Seland JH. Simultaneous, bilateral rhegmatogenous retinal detachment. Acta Ophthalmologica Scandinavica. 2000; 78:354–358.

14. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6:2012–2021.

15. Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015; 122:579–588.

TOOLS

Similar articles